Revision of USP <1099> Limit on Number of Large Deviations When Assessing Content Uniformity in Large Samples
Recommendation
3/4 February 2026
Evaluation, Implementation and Use of Suitable Technologies
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In the Pharmacopeial Forum, PF 47(4), a proposal of USP Chapter <1099> Limit on Number of Large Deviations When Assessing Content Uniformity in Large Samples has been published for comments.
The proposal is based on the version of the monograph official as of March 1, 2019, but the chapter was completely revised.
According to the USP, the new chapter "is presented with a general approach that provides a process for evaluating the number of observed results that fall outside defined limits. The approach can also be used for tests that are inherently pass/fail in nature. It should be noted that the procedure described in this chapter is not intended as a batch release test for content uniformity nor as a replacement of or alternative to Uniformity of Dosage Units <905> for compendial purposes."Comments on the chapter can be submitted from now on. The comment deadline is September 30, 2021.
The draft can be viewed here. (Please note: a one-time registration is required to access the Pharmacopeial Forum.)
Related GMP News
17.12.2025FDA Form 483: Excel-Based Data Falsification and Duplicate Log Books
17.12.2025Questions and Answers on System Suitability Tests (SST) - Part 1
17.12.2025PharmaLab 2025: Brief Summary of AQCG Track - Save the Date for 2026!
17.12.2025FDA Warning Letter Criticises Handling of OOS Results at a Contract Laboratory
17.12.2025FDA Warning: No Recall Conducted Despite Confirmed Benzene Impurity
10.12.2025FDA Warning Letter: 1,500 OOS Results with Numerous Inadequate Investigations